Time will tell Itsa.
Prof Voit was part of the PR roadshow when Phase 2A readouts we’re published.
Was there conflict of interest there?
He is a KOL in the DMD space.
ATL1102 is an anti-inflammatory…different class of drug than Exondys and GT.
If Sarepta is part of the deal…there is no conflict.
.
Where others have failed will Atl1102 succeed ?, page-900
-
- There are more pages in this discussion • 197 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6056 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 227693 | 2 |
View Market Depth
| Last trade - 10.12am 20/06/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable